Christine Hauser

Elevated Hypothalamic TCPTP in Obesity Contributes to Cellular Leptin Resistance

Kim Loh, Atsushi Fukushima, Xinmei Zhang, Sandra Galić et autres

Abstract 532: Circulating tumor DNA and outcomes with lutetium-PSMA in advanced prostate cancer: Preliminary results from an Australian study

Heidi Fettke, Nicole Ng, Christine Hauser, Patricia E. Bukczynska et autres

Abstract Recent clinical trials have revealed that Lutetium PSMA-617 (Lu-PSMA, a small molecular inhibitor of prostate-specific membrane antigen radiolabelled with the beta emitter 177-Lutetium) significantly improves clinical outcomes including overall survival for patients with metastatic castration resistant prostate cancer (mCRPC). Nevertheless, owing …

au (code pays fourni par la source)

Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).

Andrea Knox, Heidi Fettke, Christine Hauser, Patricia E. Bukczynska et autres

150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is of increasing relevance. However, the influence of age on the detection of relevant genomic alterations is incompletely understood. In this study, we …

au, us (code pays fourni par la source)

Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).

Heidi Fettke, Christine Hauser, Edmond M. Kwan, Chao Dai et autres

153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports. Whether DDR alterations are predictive of outcomes with therapeutic agents other than PARP inhibitors in mCRPC is also poorly understood. With increasing use of …

au, us (code pays fourni par la source)

177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew On Wah Yam, Andrew V Nguyen et autres

Background:177Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and combination therapies may improve outcomes. We report the final safety and efficacy results of a phase I/II study combining Lu-PSMA-617 with idronoxil (NOX66), …

au, nz (code pays fourni par la source)

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration‐resistant prostate cancer

Heidi Fettke, Edmond M. Kwan, Patricia E. Bukczynska, Jason A. Steen et autres

BACKGROUND: The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease and castration-resistant prostate cancer. However, its significance as a biomarker in metastatic castration-resistant …

au, gb (code pays fourni par la source)

Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

Edmond M. Kwan, Chao Dai, Heidi Fettke, Christine Hauser et autres

PURPOSE Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs in plasma cell–free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, we …

au, us (code pays fourni par la source)

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer

Edmond M. Kwan, Heidi Fettke, Megan Crumbaker, Maria M. Docanto et autres

Background: As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive prostate cancer (mHSPC). The value of whole blood RNA to detect candidate biomarkers in mHSPC remains largely …

au, gb (code pays fourni par la source)

Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.

Edmond M. Kwan, Chao Dai, Heidi Fettke, Christine Hauser et autres

159 Background: Tumour tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the phosphatidylinositol-3-kinase (PI3K)/Akt-signaling pathway. However, identifying CNVs in plasma cell-free DNA (cfDNA) has proven challenging. With emerging data supporting Akt inhibition in PTEN-deficient mCRPC, cfDNA …

au, us (code pays fourni par la source)

Genomic landscape of older versus younger men with metastatic castration-resistant prostate cancer

Andrea Knox, Heide Fettke, Christine Hauser, Patricia E. Bukczynska et autres

Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer

Heidi Fettke, Edmond M. Kwan, Patricia E. Bukczynska, Nicole Ng et autres

au, gb (code pays fourni par la source)

Analytical Validation of an Error-Corrected Ultra-Sensitive Ctdna Next-Generation Sequencing Assay

Heidi Fettke, Jason A. Steen, Edmond M. Kwan, Patricia E. Bukczynska et autres

Plasma circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive means to perform molecular tumor typing. Here we developed a custom ultra-sensitive ctDNA next-generation sequencing assay using molecular barcoding technology and off-the-shelf reagents combined with bioinformatics tools for enhanced ctDNA …

au (code pays fourni par la source)